Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Underweight on Fastenal, Lowers Price Target to $42

Morgan Stanley analyst Joshua Pokrzywinski maintains Fastenal (NASDAQ:FAST) with a Underweight and lowers the price target from $43 to $42.
byBenzinga Newsdesk
January 6, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Morgan Stanley analyst Joshua Pokrzywinski maintains Fastenal (NASDAQ:FAST) with a Underweight and lowers the price target from $43 to $42.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Johnson & Johnson Unit Janssen Announced New STELARA Long-Term Data Support Its Established Safety Profile In Inflammatory Bowel Disease And Durable Efficacy In Ulcerative Colitis

By Charles Gross
March 4, 10:58 AM
he Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn's disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extensi

JNJ